Seminars in Oncology
Volume 33 , Pages 1-2 , February 2006

Introduction

  • Francine Foss

      Affiliations

    • Yale Cancer Center Department of Medical Oncology 333 Cedar St New Haven, CT 06520
    • ,
  • Sean Whittaker

      Affiliations

    • St Johns Institute of Dermatology Guys and St Thomas’ Hospital London, UK

References 

  1. Whittemore AS , Holly EA , Lee IM , et al.   Mycosis fungoides in relation to environmental exposures and immune response (A case-control study) . J Natl Cancer Inst . 1989;81:1560–1567
  2. Tuyp E , Burgoyne A , Aitchison T , et al.   A case-control study of possible causative factors in mycosis fungoides . Arch Dermatol . 1987;123:196–200
  3. Weinstock MA . Epidemiology of mycosis fungoides . Semin Dermatol . 1994;13:154–159
  4. Pascual J , Torrelo A , Teruel JL , et al.   Cutaneous T cell lymphomas after renal transplantation . Transplantation . 1992;53:1143–1145
  5. Kaufman D , Gordon LI , Variakojis D , et al.   Successfully treated Hodgkin’s disease followed by mycosis fungoides (Case report and review of the literature) . Cutis . 1987;39:291–296
  6. Myskowski PL . Cutaneous T-cell lymphoma and human immunodeficiency virus (The spectrum broadens) . Arch Dermatol . 1991;127:1045–1047
  7. Kaye FJ , Bunn PA , Steinberg SM , et al.   A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides . N Engl J Med . 1989;321:1784–1790
  8. Duvic M , Martin AG , Kim Y , et al.   Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma . Arch Dermatol . 2001;137:581–593
  9. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals. Dr Whittaker has served as a consultant to Zeneus, Genmab, and Ligand.

PII: S0093-7754(05)00508-7

doi: 10.1053/j.seminoncol.2005.12.014

Seminars in Oncology
Volume 33 , Pages 1-2 , February 2006

Article Tools